Free Trial
NYSE:DVA

DaVita Q3 2025 Earnings Report

DaVita logo
$127.93 -3.11 (-2.37%)
Closing price 10/8/2025 03:59 PM Eastern
Extended Trading
$127.63 -0.30 (-0.23%)
As of 05:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DaVita EPS Results

Actual EPS
N/A
Consensus EPS
$3.29
Beat/Miss
N/A
One Year Ago EPS
N/A

DaVita Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DaVita Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, October 28, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

DaVita Earnings Headlines

Brokerages Set DaVita Inc. (NYSE:DVA) Price Target at $158.00
Bitcoin grabs headlines, but smart money likes this token
Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.tc pixel
Is DaVita Stock Underperforming the Nasdaq?
See More DaVita Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DaVita? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DaVita and other key companies, straight to your email.

About DaVita

DaVita (NYSE:DVA) (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions. The company’s growth has broadened its footprint across the United States and into select international markets, enabling it to serve a diverse patient population. DaVita leverages clinical protocols, integrated care teams and telehealth capabilities to enhance treatment consistency and improve health outcomes.

DaVita places a strong emphasis on clinical quality and patient-centered care, operating under stringent regulatory standards and collaborating closely with physicians, hospitals and payers. The company has introduced various initiatives aimed at reducing hospitalization rates, managing complications and promoting patient independence through home therapies. Its data-driven approach supports continuous improvement in care delivery and resource utilization across its network of facilities.

The company’s leadership team is headed by President and Chief Executive Officer Javier Rodriguez, who oversees DaVita’s strategic direction and operational execution. Under his guidance, DaVita continues to pursue innovations in kidney care, digital health and value-based care models, with the goal of advancing treatment accessibility and driving long-term sustainability in the renal healthcare market.

View DaVita Profile

More Earnings Resources from MarketBeat